Universal Biosensors, Inc. announced that it has recruited it's last patient and completed enrolment for its 360-patient "Xprecia Prime" PT/INR blood coagulation clinical study. The clinical study protocol was discussed at a FDA Pre Submission meeting and patients were enrolled accros the prescribed PT/INR measuring ranges. The study was conducted at five Clinical Sites in the USA.

The study is designed to provide clinical evidence as to the performance and safety of Xprecia Prime and will be used in UBI's 510K submission to the FDA, which is expected to be lodged during first quarter of 2023.